Junwei Su

3.2k total citations · 1 hit paper
48 papers, 722 citations indexed

About

Junwei Su is a scholar working on Infectious Diseases, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Junwei Su has authored 48 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 14 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Junwei Su's work include COVID-19 Clinical Research Studies (13 papers), SARS-CoV-2 and COVID-19 Research (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Junwei Su is often cited by papers focused on COVID-19 Clinical Research Studies (13 papers), SARS-CoV-2 and COVID-19 Research (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Junwei Su collaborates with scholars based in China, United States and Hong Kong. Junwei Su's co-authors include Kaijin Xu, Yunqing Qiu, Biao Zhu, Lingjuan He, Lin Liu, Xi Yang, Tingbo Liang, Rui Luo, Xingjiang Hu and Xiaoyang Lu and has published in prestigious journals such as Advanced Materials, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Junwei Su

40 papers receiving 714 citations

Hit Papers

Using patient-derived organoids to predict locally advanc... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
    2023 110 citations Hanmin Wang, Junwei Su et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junwei Su China 12 285 167 137 122 107 48 722
Kai Dai China 10 207 0.7× 176 1.1× 70 0.5× 91 0.7× 66 0.6× 19 484
E.P. Oliveira Brazil 8 201 0.7× 103 0.6× 120 0.9× 106 0.9× 66 0.6× 19 466
Kaihuan Yu China 11 453 1.6× 156 0.9× 211 1.5× 88 0.7× 66 0.6× 31 718
Eduardo Ramacciotti United States 24 183 0.6× 103 0.6× 109 0.8× 73 0.6× 125 1.2× 82 1.4k
Markus Wiedmann Norway 10 365 1.3× 60 0.4× 218 1.6× 97 0.8× 60 0.6× 29 1.3k
Wenlin Cheng China 14 323 1.1× 162 1.0× 214 1.6× 92 0.8× 64 0.6× 33 891
Jean‐Marie Leclerc Canada 18 91 0.3× 320 1.9× 177 1.3× 135 1.1× 72 0.7× 57 1.1k
Rong Yao China 13 195 0.7× 79 0.5× 87 0.6× 129 1.1× 113 1.1× 42 700

Countries citing papers authored by Junwei Su

Since Specialization
Citations

This map shows the geographic impact of Junwei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junwei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junwei Su more than expected).

Fields of papers citing papers by Junwei Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junwei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junwei Su. The network helps show where Junwei Su may publish in the future.

Co-authorship network of co-authors of Junwei Su

This figure shows the co-authorship network connecting the top 25 collaborators of Junwei Su. A scholar is included among the top collaborators of Junwei Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junwei Su. Junwei Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Dan, Junwei Su, Shuo Du, et al.. (2025). Function and structure of broadly neutralizing antibodies against SARS-CoV-2 Omicron variants isolated from prototype strain infected convalescents. Journal of Translational Medicine. 23(1). 212–212. 1 indexed citations
2.
Li, Zhiqiang, Junwei Su, Xianzhen Dong, et al.. (2025). Hydrogen-releasing electroactive nerve guidance conduits promote peripheral nerve regeneration by remodeling the microenvironment. Biomaterials. 327. 123752–123752.
3.
Su, Junwei, Xiang Liu, Yongzheng Guo, et al.. (2024). Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study. Infectious Diseases and Therapy. 13(4). 727–744. 2 indexed citations
4.
Hu, Yuanyuan, Shuo Wang, Li Ren, et al.. (2024). Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent. Pathogens. 13(4). 272–272. 1 indexed citations
5.
6.
Zu, Cheng, et al.. (2024). Outcome of Pneumocystis Jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies. BMC Infectious Diseases. 24(1). 1147–1147.
7.
Shen, Xiaomin, Junwei Su, Zhenyu Yao, et al.. (2023). Revisiting artificial intelligence diagnosis of hepatocellular carcinoma with DIKWH framework. Frontiers in Genetics. 14. 1004481–1004481. 8 indexed citations
8.
Wang, Zheng, Dan Li, Yeping Sun, et al.. (2023). Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents. Frontiers in Immunology. 14. 1160283–1160283. 6 indexed citations
9.
Chen, Ying, Zheng Wang, Junwei Su, et al.. (2023). Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort. Pathogens. 12(10). 1254–1254. 1 indexed citations
10.
Xiao, Fa-Man, Yuqing Chen, Yufa Li, et al.. (2023). Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement. Cancer Treatment and Research Communications. 35. 100707–100707.
11.
Feng, Weineng, Zihao Chen, Junwei Su, et al.. (2023). Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer. Lung Cancer. 178. 66–74. 11 indexed citations
12.
Chen, Ying, et al.. (2022). Transient HIV Reservoirs and Interleukin-6 Increase After Anti-Programmed Death-1 Antibody Infusion in HIV Patients with Lung Cancer. SHILAP Revista de lepidopterología. 2 indexed citations
13.
14.
Su, Junwei, Zhi Xie, Hanmin Wang, et al.. (2022). Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer. Thoracic Cancer. 13(11). 1619–1630. 11 indexed citations
15.
Liu, Xiang, et al.. (2022). Lenalidomide Improves Cognitive Function and Reduces Immune Reconstitution Inflammatory Syndrome in HIV-1-Related Cryptococcal Meningitis. Journal of Inflammation Research. Volume 15. 2891–2899. 2 indexed citations
16.
Yu, Xiao, Ye Jin, Wangxiao Zhou, et al.. (2022). Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology. 11. 761192–761192. 33 indexed citations
17.
Chen, Yanfei, Cheng Ding, Ling Yu, et al.. (2021). One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection. BMC Medicine. 19(1). 191–191. 50 indexed citations
18.
19.
Ni, Qin, Cheng Ding, Yongtao Li, et al.. (2020). Effect of low-to-moderate dose glucocorticoids on viral clearance in COVID-19: a retrospective study. 13(1). 21–24. 4 indexed citations
20.
Su, Junwei, Xiaomin Shen, Qin Ni, et al.. (2020). Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS. AIDS. 34(10). 1575–1576. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kai Dai Breakdown of academic impact, for papers by E.P. Oliveira Breakdown of academic impact, for papers by Kaihuan Yu Breakdown of academic impact, for papers by Eduardo Ramacciotti Breakdown of academic impact, for papers by Markus Wiedmann Breakdown of academic impact, for papers by Wenlin Cheng Breakdown of academic impact, for papers by Jean‐Marie Leclerc Breakdown of academic impact, for papers by Rong Yao
Rankless by CCL
2026